Strides to acquire Campos facility in Brazil from Aspen

Strides to acquire Campos facility in Brazil from Aspen
Bangalore-March 4, 2010 Strides Arcolab (BSE: 532531, NSE: STAR) today announced thatas part of its well articulated strategy to focus on Core Specialty injectable business, it has entered into an understanding with Aspen to acquire the facility in Campos, Brazil with related products and IPs.


The facility manufactures Penems and Penicillins and was originally divested to Aspen in 2007,at the time when company exited from LATAM operations. The facility is forecasted to deliver USD 40 Million dollar on an annualized basis. Penems is a key domain for Strides. The acquisition of Campos facility is part of a well integrated strategy for Strides with licensing and supply agreements with global partners already in place.
The consideration for the facility is approximately USD 75 Million. The acquisition would be completed subject to obtaining regulatory approvals as may be required.


Commenting on the development - Mr. Arun Kumar, Vice Chairman and Group CEO stated "Penems and Penicillins form an important part of Strides Specialty injectable business and licensing agreements for Penems have been concluded with various customers on a worldwide basis making the acquisition an important part of growing our Specialty injectable business.

Strides Arcolab Limited: Leadership Through Partnering Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore - 560076, India
BSE: 532531
NSE: STAR
Press Release
Thursday, March 4, 2010
The company has 14 manufacturing facilities across 6 countries, including its joint venture with Aspen in India and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre
located in Bangalore. Additional information is available at the company's website at www.stridesarco.com.
For further information, please contact:
Strides
Mr. Arun Kumar, Vice Chairman & Group CEO
+91 80 66580118
Mr. T.S. Rangan, Group CFO
+91 80 66580115
Mr. Kannan. N (Investors)
+91 80 66580751
Melissa Arulappan (Media)
+91 98450 22389
PR Consultancy
Mahesh Nair, Corporate Voice/Weber Shandwick
+91 9880376648
[email protected]
Kasturi Wasmatkar
+91 9916728393
[email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.